Kwon Kyu-chan, CEO of DXVX"Anticancer Vaccine, a UK subsidiary, launches Phase 1b within this year."


| Expected to be introduced within this year…Direct clinical trials in Asia

|"Human 'Cancer Conquering' dreams can be realized when developed"

| 20 Global Big Pharma Meetings at CPHI

"We are planning to introduce 'OVM-200', an anti-cancer vaccine candidate, from Oxford Vaccines (hereinafter referred to as OVM), a subsidiary within this year. After that, we would like to conduct OVM and clinical trials at the same time. We expect both clinical trials to begin within this year."

Kwon Kyu-chan, CEO of DX&VX, met at the CCPHI 2023 site in Barcelona, Spain, from the 24th to the 26th (local time).

Kwon Kyu-chan, CEO of DX&VX, met with a reporter during the "CPHI Worldwide 2023" in Barcelona, Spain, from the 24th to the 26th (local time) and made the remarks about the remaining plans within the year.

OVM is a spin-off company from Oxford University in the UK, and DX&VX secured about 43% of its stake in 2018 and became the largest shareholder. Anti-cancer vaccines are being developed based on ROP (Recombinant Redundant Peptide) technology. Currently, the anticancer vaccine has completed phase 1a clinical trial in the first half of this year and is about to start phase 1b. Phase 1b plans to be implemented in a way that OVM leads in Asia and India, including the UK and DX&VX in Korea and China. First of all, a satisfactory result was obtained in phase 1a. A recent research paper was also published in an online journal (Advanced Therapeutics).

CEO Kwon said, "We held about 20 meetings with Global Big Pharma at CCPHI, and they showed great interest in anti-cancer vaccines," adding, "There were many inquiries about joint research investments."

This is because OVM-200 is highly competitive. Vaccines are divided into preventive and therapeutic use, and OVM-200 is a therapeutic vaccine. CEO Kwon said, "The therapeutic vaccine enters the body and eliminates cancer cells," adding, "Even if new cancer cells are created over time, the T-cell in the body remembers and eliminates them."

Other differentiating factors are the fact that ROP technology applied to anti-cancer vaccines significantly increases immunity and increases vaccine effectiveness, targets Survivin, which most cancers have, and that a large number of people who have experienced the entire process from development of new drugs to commercialization have joined. CEO Kwon is also a leading global drug development expert in Korea who led the U.S. FDA (Food and Drug Administration) approval process for Hanmi Pharmaceutical's first bio-drug "Rolvedon" in Korea's anticancer field.

CEO Kwon said, "Serbibin is a good target in that it is involved in cancer cell proliferation," adding, "Although other companies have tried the same structure, few companies have successfully completed phase 1."

In particular, OVM is the only peptide technology that makes servivin target vaccines, he said. "If we add our clinical development capabilities to this, it can speed up." It also plans to prepare conditional commercialization. CEO Kwon said, "If we get good results in Phase 1b of clinical trials, we will push for approval of the Ministry of Justice in Asia (DX & VX clinical trials)," adding, "If this happens, it will be possible to enter the market as soon as possible." At the same time, we would like to proceed with approval throughout the world by conducting phase 3 clinical trials at the same time, he said.

CEO Kwon was confident that OVM-200 could be a "dream vaccine." "Internally, we believe that OVM-200 is also a possible vaccine for prevention," he said. In other words, it is possible to prevent and treat cancer, he said. "With development, we can realize the human dream of conquering cancer."

It is said that DX&VX's companion diagnostics also received great attention at this CPHI. Recently, the FDA requires companion diagnostics in the process of developing anticancer drugs. CEO Kwon said, "Now, when developing anticancer drugs, we must conduct companion diagnostics unconditionally," adding, "We have confirmed the high interest of global companies in our new drug development capabilities, with many discussions on how to enter the global market for the companion diagnostics project." DX&VX has about 400,000 clinical genome analysis data in the field of prenatal and postnatal tests, and based on this, it has the technology to find various diseases, including cancer. In addition, it has secured know-how in developing new drugs. These are major resources for discovering biomarkers (biological indicators), which are the core of new drug development.

CEO Kwon plans to actively grow the "new medicine" piece at DX&VX, which aims to become a "comprehensive healthcare provider in the pre-life period." Since August, DX&VX has switched to the representative system of Kwon, the general manager of new drug development, and Lee Yong-gu, the general manager of sales. CEO Kwon said, "I joined DX&VX after receiving the mission to 'instill new drugs,'" adding, "The goal is to secure more than three new drug candidates for phase 2 or higher clinical trials within the next three years." "We will actively sign global partnerships," he said. "Based on this, we will become a global player playing on a bigger stage."

Source:moneytoday news